Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3929 results
Aileron starts dosing in Phase I cancer trial of ALRN-6924
By PBR Staff Writer
US-based biopharmaceutical firm Aileron Therapeutics has started dosing in its Phase I clinical trial of ALRN-6924 to treat cancer patients.
Drug Research > Drug Discovery & Development > News
CEL-SCI gets clearance in Philippines to begin Phase III head and neck cancer trial of Multikine
By PBR Staff Writer
US-based CEL-SCI has received approval from the Philippines Regulatory Agency (PFDA) to begin patient enrollment in the Phase III trial of its investigational cancer immunotherapy Multikine (Leukocyte Interleukin, Injection) in the Philippines to treat head and neck cancer.
Drug Research > Drug Discovery & Development > News
Aurinia to start open label trial to evaluate impact of voclosporin in lupus nephritis
By PBR Staff Writer
Canada-based Aurinia Pharmaceuticals will start an open label, exploratory trial (AURION) to evaluate the short-term predictors of response using voclosporin in combination with mycophenolate mofetil in patients with active lupus nephritis.
Drug Research > Drug Discovery & Development > News
CrystalGenomics' osteoarthritis drug Acelex gets approval in South Korea
By PBR Staff Writer
The Korean Ministry of Food and Drug Safety (MFDS) has granted approval for South Korean biopharmaceutical firm CrystalGenomics' first, tissue-specific once-a-day drug Acelex (polmacoxib) to treat osteoarthritis.
Drug Research > Drug Discovery & Development > News
Cochrane confirms clinical efficacy of Chondroitin sulfate to treat osteoarthritis
The Cochrane Library recently published a review of chondroitin sulfate that confirms the efficacy and safety of this drug in the treatment of osteoarthritis (OA).
Drug Research > Drug Discovery & Development > News
Helsinn begins Phase IIB clinical dose-finding trial of elsiglutide
Zealand Pharma and Helsinn Healthcare jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID).
Drug Research > Drug Discovery & Development > News
PharmaCyte begins development of diabetes treatment with first preclinical study
PharmaCyte Biotech, officially moved beyond the discussion of a diabetes treatment to planting its flag in the multi-billion dollar diabetes industry with its recent announcement that the company has started the first of its preclinical trials related to developing a diabetes treatment.
Drug Research > Drug Discovery & Development > News
Rich Pharmaceuticals completes manufacturing of RP-323 study drug
Rich Pharmaceuticals (RCHA), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.
Drug Research > Drug Discovery & Development > News
Abbvie reports top-line results from phase III trial of all-oral hepatitis C treatment in Japan
AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.
Drug Research > Drug Discovery & Development > News
Intercept gets FDA breakthrough therapy status for Obeticholic acid to treat NASH with liver fibrosis
Intercept Pharmaceuticals, announced that its investigational product obeticholic acid (OCA) has received "breakthrough therapy designation" from the U.S. Food and Drug Administration (FDA) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Drug Research > Drug Discovery & Development > News
Sumitomo Chemical develops SumiLarv 2 MR to prevent dengue fever
Sumitomo Chemical is pleased to announce that it has developed SumiLarv 2 MR, a novel, long - lasting larvicide formulation that is effective in preventing dengue fever.
Drug Research > Drug Discovery & Development > News
AgeneBio secures ADDF grant for new approach to delaying onset of Alzheimer's Dementia
AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage of Alzheimer's disease, and other neurological and psychiatric diseases, announced that the company has received a $900,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF).
Drug Research > Drug Discovery & Development > News
CEL-SCI secures approval in Romania to start Phase III Multikine trial
By PBR Staff Writer
US-based CEL-SCI has received clearance from the Romanian Ministry of Health to start patient enrollment in its Phase III trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) to treat advanced primary head and neck cancer.
Drug Research > Drug Discovery & Development > News
Opsona starts OPN-305 Phase I/II trial to treat myelodysplastic syndrome
By PBR Staff Writer
Opsona Therapeutics has commenced a Phase I/II clinical trial of its lead drug candidate, OPN-305, in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) patients.
Drug Research > Drug Discovery & Development > News
CytRx reports overall survival results from phase IIb trial of aldoxorubicin
CytRx, a biopharmaceutical research and development company specializing in oncology, announced encouraging overall survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).
Drug Research > Drug Discovery & Development > News
61-75 of 3929 results